Daniel A. Pollyea
Stanford University Cancer Center, USA
Investigator initiated Phase I/II clinical trial of azacitidine in combination with lenalidomide for elderly, previously untreated AML patients (PI), Characterization of the structure, function and prognostic value of the TET2 gene in myeloid malignancies.